6/22/2021  9:59:56 PM Chg. -2.29 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
238.38USD -0.95% 28,820
Turnover: 6.87 mill.
-Bid Size: - -Ask Size: - 13.12 bill.USD 0.00% 64.98

Business description

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to helps clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring in post-surgical wards, reduce rapid response activations and costs.
 

Management board & Supervisory board

CEO
Joe E. Kiani
Management board
Micah Young, Anand Sampath, Bilal Muhsin, Jon Coleman, Tao Levy, Tom McClenahan, Yongsam Lee
Supervisory board
Joe E. Kiani, Adam Mikkelson, Craig B. Reynolds, Dr. Julie A. Shimer, Dr. Steven J. Barker, H. Michael Cohen, Sanford Fitch, Thomas Harkin
 

Company data

Name: Masimo Corp.
Address: 52 Discovery,Irvine, California 92618, USA
Phone: +1-949-297-7000
Fax: -
E-mail: -
Internet: www.masimo.com
Industry: Healthcare
Sector: Healthcare Providers
Sub sector: Healthcare Providers
End of financial year: 12/31
Free Float: 60.90%
IPO date: -

Investor relations

Name: Eli Kammerman
IR phone: +1-949-297-7077
IR Fax: -
IR e-mail: ekammerman@masimo.com

Main Shareholders

Freefloat
 
60.90%
BlackRock, Inc.
 
15.10%
Joe Kiani
 
8.60%
The Vanguard Group, Inc.
 
8.40%
FMR, LLC
 
7.00%